Adenocarcinoma da transição esofagogástrica: análise multivariada da morbimortalidade cirúrgica e terapia adjuvante

Tercioti-Júnior, Valdir; Lopes, Luiz Roberto; Coelho-Neto, João de Souza; Carvalheira, José B.C.; Andreollo, Nelson Adami

doi:10.1590/s0102-67202012000400004

Cited by 3 publications

(1 citation statement)

References 17 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 2 Esophagogastric junctional adenocarcinoma (EGJA) describes tumors with a center within 5.0 cm proximal or distal from the cardia, which is a rare but often lethal situation and had become a very serious public health problem in recent decades. 3 , 4 Several studies have reported that the incidence of EGJA has rapidly increased since the early 1970s in many regions worldwide. 5 , 6 Most EGJA patients are diagnosed at the regional or distant stage, presenting with 12% and 2% overall 5-year survival rates, respectively.…”

Section: Introductionmentioning

confidence: 99%

A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma

Song

Xie

et al. 2017

Exp Mol Med

View full text Add to dashboard Cite

The primary purpose of this study was to explore the short-term efficacy of different cisplatin and fluorouracil-based chemotherapy regimens in the treatment of patients with esophagogastric junctional adenocarcinoma (EGJA) using a network meta-analysis (NMA). Randomized controlled trials (RCTs) related to chemotherapy regimens based on cisplatin and fluorouracil for EGJA were included from the PubMed, EMBASE and Cochrane Library electronic databases (from inception to June 2016). Direct and indirect evidence were combined to calculate the pooled odds ratio (OR) and its 95% confidence interval (95% CI) as well as to draw the surface under the cumulative ranking (SUCRA) curves. This NMA finally enrolled ten eligible RCTs with the following five regimens: cisplatin plus fluorouracil (cisplatin+fluorouracil), cisplatin+fluorouracil-based chemotherapy (cisplatin+fluorouracil+docetaxel/epirubicin/irinotecan), fluorouracil-based chemotherapy (fluorouracil+docetaxel/doxorubicin/methotrexate/irinotecan), cisplatin-based chemotherapy (cisplatin+docetaxel/epirubicin/irinotecan/capecitabine/s-1) and other drug-based chemotherapy (docetaxel/irinotecan/capecitabine). These results revealed that compared with a cisplatin+ fluorouracil-based chemotherapy regimen, the fluorouracil-based chemotherapy regimen had a lower overall response rate (ORR) and partial response (PR) for EGJA patients (ORR: OR=0.43, 95% CI=0.22–0.86; PR: OR=0.46, 95% CI=0.23–0.91). Cluster analyses suggested that the cisplatin+fluorouracil-based chemotherapy regimen had the best short-term efficacy for EGJA in terms of the complete response (CR), PR, ORR, stable disease (SD) and progression disease (PD). Our results indicated that cisplatin+fluorouracil-based chemotherapy regimens may have the best short-term efficacy in the treatment of EGJA.

show abstract

Section: Introductionmentioning

confidence: 99%

A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma

Song

Xie

et al. 2017

Exp Mol Med

View full text Add to dashboard Cite

show abstract

Terapia adjuvante associada à esofagectomia melhora a sobrevida nos pacientes portadores de adenocarcinoma da junção esofagogástrica?

Tercioti-Júnior

Lopes

Sallum

et al. 2013

ABCD, arq. bras. cir. dig.

Self Cite

View full text Add to dashboard Cite

Epidemiological features of esophageal cancer. Squamous cell carcinoma versus adenocarcinoma

et al. 2014

View full text Add to dashboard Cite

PURPOSE:To analyze the epidemiological features of patients with esophageal cancer according to the histopathological types: squamous cell carcinoma or adenocarcinoma. METHODS:A total of 100 patients with esophageal cancer, being 50 squamous cell carcinomas and 50 adenocarcinomas were analyzed for demographics, nutritional factors, lifestyle habits, benign pathological conditions associated, like Barrett's esophagus and megaesophagus, tumor stage and survival rates. The nutritional factors evaluated included body mass index, percent weight loss, hemoglobin and albumin serum levels. RESULTS:Esophageal cancer occurred more often in men over 50 years-old in both histological groups. No significant differences on age and gender were found between the histological groups. Squamous cell carcinoma was significantly more frequent in blacks than adenocarcinoma. Alcohol consumption and smoking were significantly associated with squamous cell carcinoma. Higher values of body mass index were seen in patients with adenocarcinoma. Barrett's esophagus was found in nine patients (18%) with adenocarcinoma, and megaesophagus in two patients (4%) with squamous cell carcinoma. The majority of patients were on stages III and IV in both histological groups. The mean survival rates were 7.7 ± 9.5 months for patients with squamous cell carcinoma and 8.0 ± 10.9 months for patients with adenocarcinoma. No significant differences on tumor stage and survival rates were detected between the histological groups.CONCLUSION: Epidemiological features are distinct for the histopathological types of esophageal cancer. Squamous cell carcinoma is associated with black race, alcohol and smoking, while adenocarcinoma is related to higher body mass index, white race and Barrett's esophagus.

show abstract

Adenocarcinoma da transição esofagogástrica: análise multivariada da morbimortalidade cirúrgica e terapia adjuvante

Abstract: Tumoral recurrence, lymphnode metastasis and broncopneumonia in the postoperative period were factors of bad prognosis and contributed significantly to increase morbimortality and decrease global survival.

Cited by 3 publications

References 17 publications

A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma

A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma

Terapia adjuvante associada à esofagectomia melhora a sobrevida nos pacientes portadores de adenocarcinoma da junção esofagogástrica?

Epidemiological features of esophageal cancer. Squamous cell carcinoma versus adenocarcinoma

Contact Info

Product

Resources

About